POTENTIAL AND CLINICALLY SIGNIFICANT CYP3A4 MEDIATED DRUG INTERACTIONS IN HOSPITALIZED PATIENTS: A CROSS-SECTIONAL OBSERVATIONAL STUDY
Keywords:
Drug interactions, Cytochrome P450, CYP3A4, Drug metabolism, Potential interaction, Clinically significant interactionAbstract
Background:
Drug interactions occur due to the simultaneous administration of pharmacological agents that affect the efficacy of concomitant drugs.
Objective:
Estimate the prevalence of CYP3A4 enzyme-mediated drug interactions in a tertiary care hospital along with a focus on clinical significance.
Materials and Methods:
An observational cross-sectional study was conducted over three months. A total of 180 patients with polypharmacy and two or more CYP3A4-mediated drugs in the prescription were included. Data collected from patient case sheets and drug-drug interactions were analyzed using Micromedex, SuperCYP database, and literature along with consideration of personal habits (smoking and alcohol).
Results:
Among 180 patients, 132 CYP3A4-mediated drug interactions were noted. The prevalence of CYP3A4 interactions was 50.56%, with 40.56% being drug-drug interactions, 10.5% drug-alcohol interactions, and 1.66% food-drug interactions. The most common combination of interacting drugs and clinical factors associated with interacting drugs were reported. Clinically significant interactions were observed in 13 patients.
Conclusion:
We estimated the prevalence of CYP3A4 enzyme-mediated drug interactions both potential and clinically significant, and reported accordingly. The prescriber’s understanding of CYP3A4-associated drug-drug interactions and the recognition of resultant consequences constitutes the primary approach for reducing patient distress, by timely interventions.
Downloads
References
REFERENCES
Gabay M. Drug Interactions: Scientific and Clinical Principles.
Zheng WY, Richardson LC, Li L, Day RO, Westbrook JI, Baysari MT. Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. Eur J Clin Pharmacol 2018;74(1):15–27.
Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, et al. Cytochrome P450 Enzymes and Drug Metabolism in Humans. Int J Mol Sci 2021;22(23):12808.
Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C. Prevalence and Risk of Potential Cytochrome P450–Mediated Drug-Drug Interactions in Older Hospitalized Patients with Polypharmacy. Ann Pharmacother 2013;47(3):324–32.
Deodhar M, Al Rihani SB, Arwood MJ, Darakjian L, Dow P, Turgeon J, et al. Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice. Pharmaceutics 2020;12(9):846.
Lin JH. CYP Induction-Mediated Drug Interactions: in Vitro Assessment and Clinical Implications. Pharm Res 2006;23(6):1089–116.
Kusuki K, Watanabe S, Mizuno Y. Tuberculous Addison’s disease with increased hydrocortisone requirements due to administration of rifampicin. BMJ Case Rep 2019;12(3):e228293.
Hakkola J, Hukkanen J, Turpeinen M, Pelkonen O. Inhibition and induction of CYP enzymes in humans: an update. Arch Toxicol 2020;94(11):3671–722.
Jessop JP, Russell J, DeJesus A, Bardolia C, Hanna A, Turgeon J, et al. Pharmacogenetic Testing in a 70-Year-Old Woman with Polypharmacy and Multiple Comorbidities: A Case Report. Am J Case Rep [Internet] 2023 [cited 2025 Jan 6];24. Available from: https://www.amjcaserep.com/abstract/index/idArt/938850
George J, Byth K, Farrell GC. Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol 1995;50(5):727–30.
Patel KA, Bhatt MH, Hirani RV, Patel VA, Patel VN, Shah GB, et al. Assessment of potential drug–drug interactions among outpatients in a tertiary care hospital: focusing on the role of P-glycoprotein and CYP3A4 (retrospective observational study). Heliyon 2022;8(11):e11278.
Zhou SF. Drugs Behave as Substrates, Inhibitors and Inducers of Human Cytochrome P450 3A4. Curr Drug Metab 2008;9(4):310–22.
Jia X, Zhang X, Zhou T, Sun D, Li R, Yang N, et al. Cyp3A4 *1G polymorphism is associated with alcohol drinking: A 5-year retrospective single centered population-based study in China. PLOS ONE 2023;18(12):e0295184.
Weathermon R, Crabb DW. Alcohol and medication interactions. Alcohol Res Health J Natl Inst Alcohol Abuse Alcohol 1999;23(1):40–54.
Ased S, Wells J, Morrow LE, Malesker MA. Clinically Significant Food-Drug Interactions. Consult Pharm J Am Soc Consult Pharm 2018;33(11):649–57.
Holmberg MT, Tornio A, Neuvonen M, Neuvonen PJ, Backman JT, Niemi M. Grapefruit Juice Inhibits the Metabolic Activation of Clopidogrel. Clin Pharmacol Ther 2014;95(3):307–13.
Priyanka B. SuperCYPsPred [Internet]. Available from: https://insilico-cyp.charite.de/SuperCYPsPred/index.php?site=DrugDrugInteraction
Alcohol-Medication Interactions: Potentially Dangerous Mixes.
Zaoui A, Abdelghani A, Ben Salem H, Ouanes W, Hayouni A, Khachnaoui F, et al. Early-onset severe isoniazid-induced motordominant neuropathy: a case report. East Mediterr Health J 2012;18(3):298–9.
Kaur P, Kaur A, Sinha A, Khaliq W, Dumic I, Singh A. Amiodarone‐Induced Nystagmus and Ataxia: Case Report and Systematic Review of Case Reports. J Clin Pharmacol 2023;63(12):1324–9.
Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel. J Am Coll Cardiol 2008;52(19):1557–63.
Wang M, Su C, Chan ALF, Lian P, Leu H, Hsu Y. Risk of digoxin intoxication in heart failure patients exposed to digoxin–diuretic interactions: a population‐based study. Br J Clin Pharmacol 2010;70(2):258–67.
Veltri KT, Mason C. Medication-induced hypokalemia. P T Peer-Rev J Formul Manag 2015;40(3):185–90.
Xu L, Cai M, Shi BY, Li ZL, Li X, Jin HL. A Prospective Analysis of the Effects of Enteric-Coated Mycophenolate Sodium and Mycophenolate Mofetil Co-medicated With a Proton Pump Inhibitor in Kidney Transplant Recipients at a Single Institute in China. Transplant Proc 2014;46(5):1362–5.
Hwang WJ, Tsai JJ. Acute phenytoin intoxication: causes, symptoms, misdiagnoses, and outcomes. Kaohsiung J Med Sci 2004;20(12):580–5.
Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003;107(1):32–7.
Dangi B, Davydova NY, Maldonado MA, Abbasi A, Vavilov NE, Zgoda VG, et al. Effects of alcohol-induced increase in CYP2E1 content in human liver microsomes on the activity and cooperativity of CYP3A4. Arch Biochem Biophys 2021;698:108677.
Vivean SPR, Kumar MA, Shanmugasundaram P. PROSPECTIVE STUDY ON DRUG-DRUG INTERACTIONS OF NARROW THERAPEUTIC INDEX DRUGS. . E 8.
Turner RM, Park BK, Pirmohamed M. Parsing interindividual drug variability: an emerging role for systems pharmacology. Wiley Interdiscip Rev Syst Biol Med 2015;7(4):221–41.
Published
How to Cite
Issue
Section
Copyright (c) 2025 Tropical Journal of Pharmaceutical and Life Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
https://orcid.org/0009-0000-7855-3914